Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (32)

I-04Aliénor Bergès

Model informed drug development to accelerate clinical development in life cycle innovation

Wednesday 09:45-11:15

I-06Mattia Berton

Repository of model parameters for physiologically based pharmacokinetic modelling in obese validated against triazolam and caffeine observed data

Wednesday 09:45-11:15

I-07Jantine Brussee

Population PK modelling for the iminosugar lucerastat supports dose adaptation in patients with Fabry disease and moderate to severe renal impairment

Wednesday 09:45-11:15

I-08Laura Bukkems

Relationship between factor VIII activity levels and bleeding for rFVIII-SingleChain in patients with severe hemophilia A

Wednesday 09:45-11:15

I-09Myriam Chartoire

Investigation of the design of the capsaicin cough challenge test

Wednesday 09:45-11:15

I-12Vincent Croixmarie

Dose selection and adaptation strategy in renal impaired patients for a phase 2 study with a Clinical Trial Simulation strategy

Wednesday 09:45-11:15

I-13Anna Dari

Quantifying the Persistence of Immunogenicity After a Single Dose of Ad26.COV2.S in Humans Using a Mechanistic Modeling & Simulation Approach

Wednesday 09:45-11:15

I-15Alan Faraj

Model-informed dose selection in phase-3 trials for prophylactic treatment with dalcinonacog alfa in adult and pediatric hemophilia B patients

Wednesday 09:45-11:15

I-17Thomas Frank

Population pharmacokinetic/pharmacodynamic modeling to demonstrate comparability of exposure and activity of insulin aspart Sanofi

Wednesday 09:45-11:15

I-18Aline Fuchs

The human FcRn transgenic mice Tg32 as a model for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

Wednesday 09:45-11:15

I-23Chih-hsuan Hsin

Hepatic impairment affects pharmacokinetics and pharmacodynamics of selatogrel, a novel subcutaneous P2Y12 receptor antagonist

Wednesday 09:45-11:15

I-26Angela Khodzhayev

Esophageal Eosinophil Count and the Endoscopic Reference Score Remodeling Subscore Do Not Correlate in Placebo Treated Eosinophilic Esophagitis Patients: Phase 2 Proof-of-Concept and Phase 3 TREET Studies

Wednesday 09:45-11:15

I-27Jane Knöchel

Accelerating clinical development of a novel PCSK9 antisense oligonucleotide using semi-mechanistic pharmacodynamic modelling

Wednesday 09:45-11:15

I-29Olivier Le Tilly

Non-linear pharmacokinetics of eculizumab in atypical haemolytic uremic syndrome

Wednesday 09:45-11:15

I-30Feiyan Liu

A system pharmacology Boolean network model for the TLR4-mediated host response in early sepsis

Wednesday 09:45-11:15

I-31Igor Locatelli

A Bayesian mixed treatment comparison meta-analysis of pulmonary arterial hypertension therapies

Wednesday 09:45-11:15

I-37Joo Young Na

Population pharmacokinetic analysis of omeprazole according to CYP2C19 polymorphism in elderly subjects

Wednesday 09:45-11:15

I-41Tiffany Pela

Quality of Life and Symptom Burden Among Patients With Eosinophilic Esophagitis in a Real-World Setting

Wednesday 09:45-11:15

I-42Carlos Perez-Ruixo

Population pharmacokinetic modelling of selexipag and its active metabolite after oral and intravenous administration in adult pulmonary arterial hypertension patients

Wednesday 09:45-11:15

I-43Christoph Pfaffendorf

Population pharmacokinetic model of atovaquone in infants to adults

Wednesday 09:45-11:15

I-45Elodie Plan

Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatment

Wednesday 09:45-11:15

I-47Mar Ribera I Armengol

A perspective on the kinetics of the oral administration of Mirabegron to treat overactive bladder in spinal cord injury patients

Wednesday 09:45-11:15

I-49Karine Rodriguez-Fernandez

External validation of a population pharmacokinetic model of adalimumab in patients with hidradenitis suppurativa

Wednesday 09:45-11:15

I-50Viktor Rognås

An integrated semi-mechanistic model to predict the outcome of drug-target effects on the erythropoietic system

Wednesday 09:45-11:15

I-52Marina Savelieva

Pharmacometrics and Integrated Evidence Generation: example of ligelizumab in Chronic Spontaneous Urticaria

Wednesday 09:45-11:15

I-53Daniel Seeler

Towards a qualitative systems biology model to study the effect of blood flow responsive CCM and NO signaling on endothelial cell morphology

Wednesday 09:45-11:15

I-54Sejung Hwang

Population pharmacokinetic analysis to investigate the effect of ethnicity for extrapolating data from Caucasians to Koreans in eslicarbazepine acetate therapy

Wednesday 09:45-11:15

I-55Alexander Solms

Reduced FXI levels do not appear to increase bleeding risk in End-Stage Kidney Disease patients – results from an exploratory PK/PD and ER analysis of FXI-ASO

Wednesday 09:45-11:15

I-56Gilles Tiraboschi

Population Pharmacokinetic and Pharmacodynamic Analyses of Olipudase alfa in Adult and Pediatric Patients with the rare Acid Sphingomyelinase Deficiency (Niemann-Pick) lysosomal storage disease

Wednesday 09:45-11:15

I-57Thi Quyen Tran

Population pharmacokinetics of a truncated milk fat globule-EGF factor 8 (NP-011) for optimal dose prediction on liver fibrosis

Wednesday 09:45-11:15

I-61Paul van den Berg

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis

Wednesday 09:45-11:15

I-64Zhigang Wang

Higher clearance of therapeutic antibodies is associated with worse endoscopic outcomes in patients with Crohn’s disease

Wednesday 09:45-11:15